Centred on a cure by Abraham, DJ
Professor David Abraham has focused his career on understanding fibrosis to better treat connective 
tissue diseases. Here, he discusses his current research activities and the future of biomedical research
Could you 
describe your 
role as Director 
of the Centre for 
Rheumatology 
and Connective 
Tissue Diseases at 
University College 
London (UCL), UK? 
My role is to oversee all aspects of the Centre’s 
operations, including staffing and funding, 
supervising research, publishing in scientific 
journals, submitting grant applications, and 
recruitment and appraisals. I am also responsible 
for the teaching services the Centre performs 
for the University at both undergraduate 
and postgraduate level, and to ensure that 
research students are effectively supervised 
and prepared for a career in science. In essence, 
we want to attract, retain and develop the 
most gifted students and educate, train and 
inspire them to become the next generation 
of scientists and doctors at the national and 
international forefront of biomedical research 
and patient care. 
What type of research are you conducting?
With my co-Director Professor Chris Denton, 
who is a clinician scientist, our main research 
focus is centred on the autoimmune/rheumatic 
connective tissue disease spectrum scleroderma 
(SSc). This disease has four main components: 
blood vessel damage, inflammation, 
autoimmunity and tissue scarring leading to 
widespread and organ-specific fibrosis. The 
majority of our work is aimed at understanding 
the genetic, epigenetic, molecular and cellular 
mechanisms that underlie these processes with 
a clear translational focus to identify candidates, 
which can be developed into new and more 
effective treatments for patients.
How much is known about the 
aetiology of SSc?
As with all autoimmune diseases, the precise 
aetiology of SSc is unknown. It is a complex 
condition with a multifaceted pathogenesis and 
disease spectrum. Critical features include blood 
vessel disease and inflammation. Moreover, 
Raynaud’s phenomenon is a near universal 
prodrome that occurs prior to developing SSc. 
There are also genetic components, and many 
studies have implicated an environmental 
influence, such as trauma, infection and 
exposure to toxic agents and oxidant stress. 
Therefore, in broad terms, epigenetics is widely 
believed to be important in the disease process. 
We are beginning to unravel the genetics, largely 
due to the application of new technologies such 
as genome-wide association studies. These alone 
have identified nearly 30 genes associated with 
the disease process; the most robust associations 
so far are with genes of the immune system. 
To what extent will the understanding 
of complex pathogenic links between 
vasculopathy, autoimmunity and tissue 
fibrosis inform the development and use of 
targeted therapies?
From the natural history of the disease 
process, we believe there are linked pathogenic 
mechanisms. If we can determine which cell 
types are affecting the disease at different 
points or in different ways, we can develop 
targeted therapies. For example, damage to 
the blood vessel wall appears to promote the 
immune cells to escape from the blood into 
the tissues and cause inflammation, we can 
develop therapies that protect the blood vessel 
and dampen inflammation. Likewise, if we 
identify the important growth factors that drive 
the development of the myofibroblast, we can 
attenuate scar formation. Some treatments have 
been developed that have a beneficial effect on 
the blood vessels and are effective in impacting 
upon inflammation – though there is more to 
do in these areas as the beneficial effects are 
often modest and the drugs have toxicities and 
side-effects – but to date, there are no effective 
treatments for scarring and fibrosis.
Can you describe how the Centre uses 
biobanking in its fibrosis research?
We collect samples from patients with these 
complex diseases and use them in two main 
approaches. One is genetics. With our large 
patient cohorts, we take blood samples and 
examine gene polymorphisms that associate 
with the disease and its subsets. For example, 
we study patient groups with lung fibrosis and 
ask what genes are linked to those patients 
using whole genome analysis. We then look for 
different genes in those patients compared to 
ones with SSc who do not have lung fibrosis. 
A second area is biomarkers. We look at 
biomarkers in the serum and plasma by 
performing large proteomic screens and 
assessing the entire protein complement of 
the biological fluids. We then find the proteins 
expressed there and compare those with 
serum samples from a control cohort. We can 
examine the differences between these cohorts 
and identify biomarkers – or proteins – in the 
serum and hypothesise if a patient might fall 
into a certain disease subset. 
As a member of the UCL Knowledge 
Transfer and Enterprise Board for the 
Faculty of Medical Sciences, how do you 
work to translate innovative research into 
commercial enterprise? 
Bridging research and the transfer of laboratory 
work into effective clinical applications is 
a challenge. Working closely with clinical 
colleagues in important, and in terms of 
Knowledge Transfer and Enterprise Board, I try 
to facilitate interactions between academia 
and industry. My goal is to provide the 
optimum opportunity for the best knowledge 
of the disease process to be joined with the 
best target or drug that might have an impact 
on the disease. I believe these partnerships 
will result in a greater chance of successfully 
enhancing the transition from research 
into application. There will always be a risk 
in projects, but through collaboration and 
gaining insight into the disease process, and by 
partnering with industry where cutting-edge 
technologies and unrivalled drug discovery 
expertise exist, along with critical experience 
in clinical trials and successfully bringing 
drugs to market, we believe these risks are 
substantially lowered.
Centred on a cure
Chris Denton, 
Professor of 
Experimental 
Rheumatology
PR
O
FE
SS
O
R 
D
AV
ID
 A
BR
AH
AM
 28 INTERNATIONAL INNOVATION
In which direction will you take your 
research in the future? 
We will focus mainly on fibrosis and SSc, 
and on translating or transferring our basic 
biomedical research findings into treatments. 
Over the last 10 years, we have been able 
to improve our understanding of the disease 
process occurring within SSc. We also have 
a good idea of what are likely to be the key 
cell and molecular targets driving tissue 
remodelling and fibrosis. We now have several 
targets (growth factors, kinase inhibitors and 
transcription factors) that are in patents, and 
we are moving forward in new clinical trials. 
How do you see biomedical research 
progressing in the years to come?
It is an exciting time for biomedical research. 
Technologies are available that can help us 
understand the disease process in very precise 
detail. Once we identify important mediators, 
it will be possible to develop new research 
tools, such as antibodies, inhibitors and model 
systems, with which to study pathogenesis. 
Moreover, antagonists and biologics are often 
already available, so once a target is identified, 
significant translational potential exists. 
Additionally, biomedical research is likely to 
intersect more frequently with personalised 
medicine. This is a key research domain at UCL, 
because it is important to know if drugs given 
to patients might have a disease-modifying 
effect. At the Centre, we are working to 
stratify patients into different groups based 
on their history of disease. This way, we can 
tailor treatments to some extent. If you take 
pulmonary arterial hypertension, for example, 
we are now able to identify patients by a series 
of clinical tests and biomarkers. Once we 
have identified individuals eligible for certain 
treatment programmes, we can work towards 
targeting the problems involved in pulmonary 
arterial hypertension.
Fighting 
fibrosis
Scientists in the Centre for 
Rheumatology and Connective 
Tissue Diseases at University 
College London are examining 
the mechanisms that spur 
fibrosis, with the goal of treating 
and even preventing diseases, 
such as scleroderma, that display 
scarring as a major component
THOUGH IT MAKES up every bit of fat, bone 
and cartilage in the body, when it works properly, 
connective tissue often goes unnoticed. However, 
when tissue misbehaves, it can wreak havoc 
on an individual’s everyday life, causing great 
pain, discomfort and even leading to death. 
Furthermore, while the number of connective 
tissue diseases is high – there are over 200 – there 
is a lack of effective treatments. In London, there is 
a research centre aiming to expand this knowledge 
base and improve the lives of the millions of people 
worldwide who live with connective tissue diseases. 
Research led by Professor David Abraham at the 
Centre for Rheumatology and Connective Tissue 
Diseases at University College London (UCL), UK, 
is working to understand the molecular and cell 
biology of connective tissue diseases, including 
the genetic and molecular mechanisms underlying 
tissue scarring and replacement fibrosis.
FOCUSING ON FIBROSIS
The lens through which the Centre examines 
connective tissue disease is that of fibrosis – the 
unrestrained thickening and scarring of tissue. 
Fibrosis is a common feature to this spectrum of 
diseases, which affects 80-100 million people 
across Europe, the US and Japan. In general, the 
body’s ability to produce scar tissue is a good 
thing, especially when an individual sustains an 
injury, such as a burn or a cut. To mount a healing 
response, the body activates fibroblast cells, which 
are present in all soft connective tissues. “The 
fibroblast cell undergoes a fundamental change 
in its differentiation. It becomes a synthetic 
and contractile cell – the myofibroblast. This 
cell secretes a complex protein glue called the 
extracellular matrix (ECM) and coordinates repair 
of the wound,” Abraham explains. 
Once the myofibroblast cells repair the tissue, 
they are supposed to shut off and disappear 
through apoptosis. However, in fibrotic disorders, 
this shutdown process goes awry, and the 
myofibroblasts continue to secrete ECM into the 
The emergence of new genome-
wide and large-scale analytical 
technologies is enabling the 
Centre to explore vast numbers 
of gene polymorphisms that 
associate with different disease 
subsets and organ-involvement 
on a scale that would have been 
unimaginable even 10 years ago
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The myofibroblast: visualised by atomic force microscopy 
(top panel) and by immunofluorescence, vinculin (green) 
and alpha smooth muscle actin (red). 
Royal Free Campus.
wound. Over time, this scar tissue builds up to 
the point that it overwhelms the affected organs’ 
architecture, compromising its function. This is 
a dangerous turn of events, especially in diseases 
such as pulmonary fibrosis and liver cirrhosis, as the 
organs can stop working altogether. In fact, it has 
been estimated that fibrosis plays a major role in 
nearly 50 per cent of deaths in the Western world.
A SPOTLIGHT ON SCLERODERMA
While fibrosis can develop after an injury, it has 
also been known to occur due to environmental, 
genetic and immunological responses. This is likely 
the case for scleroderma (SSc), a multi-system 
spectrum of rare chronic autoimmune diseases 
that cause swelling and pain in muscles and joints, 
as well as the tightening and hardening of skin and 
connective tissue. It is extremely fatal and, in the 
past, scientists have often called it incurable.
SSc can take two forms. In limited cutaneous SSc, 
skin fibrosis is restricted to particular sections of 
the body – mainly the extremities – and is often 
characterised with vascular manifestations. 
However, nearly 40 per cent of SSc patients have 
diffuse cutaneous SSc, in which fibrosis rapidly 
progresses to the skin, lungs and other internal 
organs. For patients, receiving a diagnosis of either 
disease is deadly news, as estimates from a recent 
UK cohort show that patients with limited and 
diffuse cutaneous SSc having survival rates of 
57 per cent and 50 per cent, respectively.
While the number of individuals who suffer 
specifically from SSc is relatively small – 75,000-
100,000 individuals in the US suffer from it – 
scientists at UCL are paying special attention to 
this condition because it is distinct from most 
fibrotic disorders. Nearly every patient with the 
disease experiences Raynaud’s phenomenon, a 
condition that affects the blood supply to certain 
parts of the body, usually the fingers and toes, as 
an early symptom. Additionally, SSc often displays 
other forms of small-vessel vasculopathy, as 
well as inflammation and autoimmunity, before 
the interstitial and vascular fibrosis starts in the 
skin, lungs and organs. This disease progression is 
significant because it means that immune cells and 
vascular dysfunction might play significant roles in 
activating the genetic programme responsible for 
fibrosis. Therefore, the UCL scientists can use these 
characteristics as natural biomarkers to indicate 
the severity of SSc and create targeted treatments. 
Excitingly, these biomarkers are not only useful 
for patients who have SSc. As fibrosis is present 
in many human diseases – and since many are 
immunologically driven and all forms of fibrosis are 
believed to progress through the same common 
stages – SSc’s biomarkers may be applicable 
to a large variety of fibrotic disorders. “Several 
biomarkers such an Interleukin-6 (and other 
cytokines), brain natriuretic peptide and some 
chemokines are currently showing promise as 
markers in fibrotic disease along with specific ECM 
proteins, their degradation products and ECM 
modifying enzymes derived from the scar tissue,” 
Abraham expands.
CREATING TREATMENTS
In addition to clinical services, the Centre 
completes many important clinical trials. Current 
treatments for SSc – and for fibrotic diseases in 
general – are aimed at slowing its progression 
and managing its complication through lifestyle 
modification and pharmacological intervention. 
Unfortunately, at most these actions only have a 
small impact on the disease pathogenesis. This is 
a reality that Abraham and his team are working 
to change: “We are driven by the desire to transfer 
our basic and applied scientific research into 
meaningful therapies”.
To achieve this remit, the Centre mainly focuses 
its research efforts on three models – in vitro, 
animal models and tissue slices. These integrate 
gene candidates and biomarkers so the team 
can test potential therapeutics. “Although much 
information has been gleaned from in vitro systems 
concerning SSc’s complexity, it is impossible to 
mimic in vitro, highlighting the need for in vivo 
models,” Abraham states. Therefore, complex 
multi-cell systems and animal models have 
been especially important to his and the Centre’s 
work. Since patients with SSc can experience 
different combinations of its four key features – 
vasculopathy, inflammation, autoimmunity and 
fibrosis – the UCL scientists are using three different 
types of animal model to examine specific aspects. 
“These range from naturally-occurring models 
of fibrosis to models that can assess fibrosis in 
different target organs. We have also developed 
new models that use genetic modification with 
gene knock-out and knock-in technologies and 
with multiple gene approaches. This is an essential 
component of biomedical research as preclinical 
models assess the influence of new therapies in 
vivo,” Abraham enthuses.
Since a major manifestation in SSc is skin fibrosis, 
damaged tissue is relatively accessible to obtain pre- 
and post-treatment. In the clinical trial world, this is 
an enviable ability because it enables researchers to 
analyse gene and protein signatures much earlier in 
the process. Through this, the clinical team in the 
Centre for Rheumatology and Connective Tissue 
Diseases is able to assess the presence of their trial’s 
various drug targets and examine their therapeutic 
potential quickly and easily.
Key to this work is Professor Chris Denton, who 
is the clinical leader of the Centre. Denton and 
Abraham work intimately together to ensure that 
the translational research the group undertakes – 
from concepts in the lab through to clinical trials 
and treating patients – is seamless. “It’s important 
that we have this collaboration between scientists 
and clinicians. A team-based approach with basic 
scientists understanding the disease process 
and clinicians at the interface of taking studies 
into clinical trials will mean better treatment for 
patients,” Abraham explains.
IMPROVING TRIALS
While much information has been gleaned about 
SSc from the phase I, II and III clinical trials performed 
by the Centre through the years, Abraham is taking 
steps to improve the effectiveness of future trials. 
For example, his team is focusing on using more 
evidence-based approaches. In these, the scientists 
are targeting the pathways and molecules involved 
in the disease process, with the goal of creating 
treatments that apply specifically to them. They 
are also in the process of conducting research, trials 
and studies that rely on patient stratification, which 
occur in clearly defined groups so that individuals 
have comparable phenotypes. Patient stratification 
will also enable the team to carry out the trials and 
studies over a much shorter timeframe.
END GOALS AND FUTURE TARGETS
A debate is raging among scientists in the 
field concerning the future of fibrosis research. 
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DAVID ABRAHAM is a Professor of Cell and 
Molecular Biology and Head of Research in 
the Department of Inflammation, UCL, where 
he is also responsible for helping to shape 
fibrosis strategy.
Normal lung (top) and scarred lung (bottom).
FLARRE
Professor David Abraham is the Steering 
Committee Chair for the UCL Consortium 
for Inflammation, Tissue Repair, Scarring 
and Fibrotic Diseases. He explains how 
the Consortium collaborates to promote 
the breadth of basic, translational and 
clinical research on fibrotic diseases
The Consortium for Inflammation, Tissue 
Repair, Scarring and Fibrotic Diseases 
(FLARRE) is a powerhouse of scientists and 
industry members all dedicated to aspects 
of fibrosis research. It grew out of my 
University College London (UCL)  Enterprise 
role as a way to assemble basic, biomedical 
and clinician researchers from across UCL 
with interests in FLARRE. It also acts to 
raise awareness of the depth and breadth 
of research being carried out, and highlight 
entrepreneurial or commercial potential. 
Essentially, I want to develop and promote 
a UCL cluster of expertise in FLARRE and 
highlight multidisciplinary skills that would 
promote synergy across the university, 
and to increase collaboration within it. 
Additionally, I aim for FLARRE to identify 
and promote the young people at UCL 
– PhD students and emerging Principal 
Investigators alike – as these are the people 
with all the new and outside-the-box ideas 
that will push the field forward. 
An important aspect of the Consortium is to 
augment commercial engagement, develop 
interaction with industry and pharma, and 
‘open-up’ FLARRE for business. In terms of 
fibrosis, there are experts across UCL for 
almost all ‘forms’ and target organs, so UCL 
is a ‘one-stop-shop’ where industry can 
help across a wide range of fibrotic diseases. 
More importantly, perhaps, is the fact that 
we can provide expertise in disease areas to 
find new targets, validate existing targets, 
and access and use of pre-clinical models 
and human samples to gain confidence in 
targets, pathways and concepts. Moreover, 
UCL has partner hospitals and many of the 
patient groups required for clinical trials can 
be made available via our clinical colleagues. 
The Consortium has several other 
important goals; for example, we want 
to enter into and enhance international 
academic collaborations, such as the fibrosis 
collaboration we have started with Yale 
University, USA. We also endeavour to act 
in the interest of patients, by facilitating 
translation of innovative research into 
commercial enterprise, and to champion 
drug repositioning through the exploration 
of therapeutic switching and drug re-tasking. 
 
www.ucl.ac.uk/flarre
Specifically, they are asking: is fibrosis reversible? 
While there is some experimental evidence that 
suggests it may be possible one day, Abraham is 
of the mind that complete reversal is unlikely, 
especially once scar tissue has overwhelmed the 
body, or in fibrotic disorders, such as SSc, where 
fibrosis develops over many years. Instead of 
focusing solely on disease reversal, Abraham is 
setting his sights on restoring organ structure 
and function, an often overlooked topic: “Let’s 
say we could reverse fibrosis or remove the 
myofibroblasts – then one would be left with an 
organ scaffold with no cells. In addition to halting 
fibrosis, we need to take a regenerative medicine 
approach to repopulate damaged organs in hand 
with antifibrotic therapies”.
Abraham and his team are also turning their 
attention to genetics and epigenetics, as it has 
become clear that both play a large role in patients’ 
susceptibility to SSc and in its progression. The 
emergence of new genome-wide and large-scale 
analytical technologies is enabling the Centre to 
explore vast numbers of gene polymorphisms that 
associate with different disease subsets and organ-
involvement on a scale that would have been 
unimaginable even 10 years ago. 
Finally, Abraham is focusing on building the 
Centre’s relationship with pharmaceutical 
companies, as fibrosis and SSc have previously 
been untouched by the industry. The relationship 
is one that would benefit both parties greatly. 
Pharmaceutical companies would be able to 
use the solid knowledge base of the underlying 
pathology of scarring that the Centre has built to 
create fibrosis inhibitors, while the Centre would 
reap the benefits of large-scale drug testing 
that is firmly within the reach of pharmaceutical 
companies. The relationship would also benefit 
patients, as Abraham states: “This partnership 
results in lasting benefits to patients because these 
new collaborations will lead to the release of novel 
drugs into the market”.
INTELLIGENCE
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